The global Human Somatotropin market was valued at US$ XX million in 2019 and is expected to reach US$ XX million by the end of 2026, growing at a CAGR of XX% during 2021-2026.
This report focuses on Human Somatotropin volume and value at the global level, regional level and company level. From a global perspective, this report represents overall Human Somatotropin market size by analysing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe, Asia-Pacific, Latin America and Middle East & Africa.

Global Human Somatotropin Market: Segment Analysis
The research report includes specific segments by region (country), by company, by Type and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2016 to 2027. Understanding the segments helps in identifying the importance of different factors that aid the market growth.

Segment by Type
Powder
Solvent

Segment by Application
Growth Hormone Deficiency (GHD)
Turner Syndrome
Chronic Renal Insufficiency
Prader Willi Syndrome
Small for Gestational Age
SHOX Deficiency
Others

By Region
North America
United States
Canada
Mexico
Europe
Germany
France
UK
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Brazil
Middle East & Africa
Turkey
GCC Countries
Egypt
South Africa

By Company
Novo Nordisk
Pfizer
Eli Lilly
Merck Serono
F. Hoffmann-La Roche
Ferring Pharmaceuticals
GeneScience Pharmaceuticals
Ipsen
LG Life Sciences
Sandoz International
Anhui Anke Biotechnology